Current and Novel Treatment Advances and their Impact on the Management of Psoriasis

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2019 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 1, 2019 to August 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Celgene, Lilly USA LLC, and Novartis Pharmaceuticals Corporation

Description:
Psoriasis is a an under-diagnosed, complex, chronic, immune-mediated inflammatory disease that affects approximately 7 million, or just over 2%, of the population in the United States. Psoriasis patients experience periodical flare-ups of sharply defined red patches, covered by a silvery, flaky surface. The disease can be quite itchy and most commonly appears on the skin of the scalp, elbow, knees, and lumbosacral areas of the body. It is a complex disease to manage and the goal should be a patient-centered treatment that reduces disease burden, improves quality-of-life, and addresses the risks of systemic complications and comorbid conditions. Co-morbidities include psoriatic arthritis, cardiovascular disease, type 2 diabetes, depression, and obesity among others. Traditional treatment options include topical creams, over the counter (OTC) medications, phototherapy, and systemic medication, which may be prescribed orally or by injection. Novel therapies include oral, small molecule medications and biologics, which are derived from living cells that have been cultivated in a laboratory. Biologics are administered subcutaneously or intravenously and target specific areas of the immune system. Recent research indicates that both IL-23 and IL-17 play important, and perhaps integral, roles in the development of psoriatic plaques. Treatments such as briakinumab, guselkumab and tildrakizumab targeting IL-23 and brodalumab, ixekizumab, and secukinumab targeting IL-17 have shown safety and good efficacy in clinical trials of moderate-to-severe plaque psoriasis, but long-term safety still needs to be established.

Upon completion of this activity, participants will be able to:

  • Analyze the clinical data regarding the safety and efficacy of new and emerging treatment options for psoriasis, specifically those therapies with IL-17/IL-23 or PDE4 pathway inhibitors

  • Discuss the appropriate tools for diagnosis, including digital options, for moderate to severe psoriasis

  • Identify multidisciplinary team roles in integrating the latest clinical data on therapies for psoriasis into clinical practice, including shared decision-making roles

  • Examine the current guideline recommendations on molecular targeted biologic therapies to make effective personalized treatment decisions

  • Assess the challenges of managing comorbid conditions in patients with psoriasis
     

Faculty: Junko Takeshita, MD, PhD, MSCE
Assistant Professor of Dermatology
Assistant Professor of Epidemiology
University of Pennsylvania Perelman School of Medicine

Disclosure:

Dr. Takeshita has received grant/research support from Pfizer. Her presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grants from
Celgene, Lilly USA LLC, and Novartis Pharmaceuticals Corporation

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue